AMRX on XNAS, Health Care, Amneal Pharmaceuticals, Inc., job postings
Measures activity, not value. Not investment advice.
Net income rose 721% to $133.3M while shares gained 83% in twelve months.
GoodLatest quarter revenue up 10% to $862.7M from a year earlier
WatchCapital spending up 158% to $31.8M in the latest quarter
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $862.7M, net loss $21.7M.
31 Dec 2021RevenueNet incomeNet losstallest bar $862.7M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$862.7M
-$21.7M
30 Jun 2026
$796.2M
$57.7M
31 Mar 2026
$722.5M
$62.3M
31 Dec 2025
$814.3M
–
30 Sep 2025
$784.5M
$2.4M
30 Jun 2025
$724.5M
$22.4M
31 Mar 2025
$695.4M
$12.2M
31 Dec 2024
$730.5M
-$20.7M
30 Sep 2024
$702.5M
-$156K
30 Jun 2024
$701.8M
$6.0M
31 Mar 2024
$659.2M
-$91.6M
31 Dec 2023
$617.0M
-$101.4M
30 Sep 2023
$620.0M
$15.5M
30 Jun 2023
$599.0M
$22.2M
31 Mar 2023
$557.5M
-$15.6M
31 Dec 2022
$609.8M
–
30 Sep 2022
$545.6M
-$7.6M
30 Jun 2022
$559.4M
-$242.1M
31 Mar 2022
$497.6M
-$8.8M
31 Dec 2021
$536.9M
–
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$3.2B
$2.9B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+8.9%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$133.3M
$16.2M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$0.42
$0.02
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
40.2%
36.8%
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
15.0%
12.2%
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
4.2%
0.6%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
–
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$88.2M
$264.3M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$157.4M
$201.2M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$2.9B
$2.6B
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$2.8B
$2.4B
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
5.5
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$1.52
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
55.2
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
2.3
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
3.2
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
13.9
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+9.6%
332 13F filers vs 303
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
49%
169.2M shares held by 13F filers (30 Sep 2026) of 348.4M outstanding (30 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
3.3%
11.4M shares sold short (30 Oct 2026) of 348.4M outstanding (30 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
2.8
11.4M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-19%
14.1M shares sold short in the report before, 11.4M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
74%
74% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 54%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
+33%
57 vs 43 applications
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+10%
$862.7M vs $784.5M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
+158%
$31.8M vs $12.3M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$1.1M
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
25
25 articles in the last 7 days; its usual week has 4 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
6.2×
25 articles in the last 7 days; its usual week has 4.
Price $21.12 on 20 Nov 2026, +83% over 12 months (12-month range $11.52 to $21.88)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $7.7M in the last 12 months (the 12 months before: -$62.5M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 56 published in the last 12 months, +27% on the 12 months before.Revenue per quarter. Revenue $862.7M in the latest quarter, +10% on a year earlier.Capital spending per quarter. Capital spending $31.8M in the latest quarter, +158% on a year earlier.Institutional holders (13F filers). 332 13F filers reported holding it in the latest 13F quarter, +40% on a year earlier.Federal obligations. Federal obligations: $0 published in the last 12 months.Lobbying spend. Lobbying spend: $1.1M published in the last 12 months, -33% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.
Quarter ended 31 Dec 2021: $536.9M, +5.3% on a year earlier; public on 2 Mar 2022
Quarter ended 31 Mar 2022: $497.6M, +0.9% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $559.4M, +4.5% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $545.6M, +3.2% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $609.8M, +14% on a year earlier; public on 4 Mar 2023
Quarter ended 31 Mar 2023: $557.5M, +12% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $599.0M, +7.1% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $620.0M, +14% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $617.0M, +1.2% on a year earlier; public on 15 Mar 2024
Quarter ended 31 Mar 2024: $659.2M, +18% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $701.8M, +17% on a year earlier; public on 10 Aug 2024
Quarter ended 30 Sep 2024: $702.5M, +13% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $730.5M, +18% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $695.4M, +5.5% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $724.5M, +3.2% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $784.5M, +12% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $814.3M, +11% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $722.5M, +3.9% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $796.2M, +9.9% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $862.7M, +10% on a year earlier; public on 10 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $17.5M, -41% on a year earlier; public on 2 Mar 2022
Quarter ended 31 Mar 2022: $10.8M, -8.3% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $5.0M, -35% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $19.1M, +79% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $11.5M, -34% on a year earlier; public on 4 Mar 2023
Quarter ended 31 Mar 2023: $9.7M, -10% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $12.0M, +138% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $11.7M, -39% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $9.9M, -14% on a year earlier; public on 15 Mar 2024
Quarter ended 31 Mar 2024: $9.2M, -5.1% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $10.6M, -11% on a year earlier; public on 10 Aug 2024
Quarter ended 30 Sep 2024: $16.9M, +45% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $15.2M, +54% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $13.2M, +43% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $22.8M, +115% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $12.3M, -27% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $21.8M, +44% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $8.2M, -38% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $30.7M, +34% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $31.8M, +158% on a year earlier; public on 10 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 141; public on 14 Feb 2022
31 Mar 2022 report: 161; public on 16 May 2022
30 Jun 2022 report: 149; public on 15 Aug 2022
30 Sep 2022 report: 143; public on 14 Nov 2022
31 Dec 2022 report: 146; public on 14 Feb 2023
31 Mar 2023 report: 139; public on 15 May 2023
30 Jun 2023 report: 124; public on 14 Aug 2023
30 Sep 2023 report: 136; public on 14 Nov 2023
31 Dec 2023 report: 145; public on 14 Feb 2024
31 Mar 2024 report: 168; public on 15 May 2024
30 Jun 2024 report: 174; public on 14 Aug 2024
30 Sep 2024 report: 176; public on 14 Nov 2024
31 Dec 2024 report: 196; public on 14 Feb 2025
31 Mar 2025 report: 225; public on 15 May 2025
30 Jun 2025 report: 228; public on 14 Aug 2025
30 Sep 2025 report: 237; public on 14 Nov 2025
31 Dec 2025 report: 263; public on 17 Feb 2026
31 Mar 2026 report: 309; public on 15 May 2026
30 Jun 2026 report: 303; public on 14 Aug 2026
30 Sep 2026 report: 332; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $28K published
Month from 1 Jan 2022: $152 published
Month from 1 Feb 2022: $451 published
Month from 1 Mar 2022: $81.4 published
Month from 1 Apr 2022: $479K published
Month from 1 May 2022: $3.7 published
Month from 1 Jun 2022: $63.8 published
Month from 1 Aug 2022: $3K published
Month from 1 Sep 2022: $1K published
Month from 1 Dec 2022: $42 published
Month from 1 Jun 2023: $27K published
Month from 1 Oct 2023: $93.1 published
Month from 1 Nov 2023: $189K published
Month from 1 Dec 2023: $2K published
Month from 1 Feb 2024: $4K published
Month from 1 Apr 2024: $246 published
Month from 1 Jun 2024: $31K published
Lobbying spend
Quarter from 1 Jan 2022: $60K published
Quarter from 1 Apr 2022: $40K published
Quarter from 1 Apr 2024: $850K published
Quarter from 1 Jul 2024: $240K published
Quarter from 1 Oct 2024: $230K published
Quarter from 1 Jan 2025: $210K published
Quarter from 1 Apr 2025: $910K published
Quarter from 1 Jul 2025: $220K published
Quarter from 1 Oct 2025: $360K published
Quarter from 1 Jan 2026: $390K published
Quarter from 1 Apr 2026: $240K published
Quarter from 1 Jul 2026: $240K published
Quarter from 1 Oct 2026: $270K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $862.7M (30 Sep 2026), 1.2× its normal quarter; higher than 100% of its own history.
Reported lobbying spend: $270K in Q3 2026, $240K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
1 Sep 2026
New
Hill East Group, LLCfor Avkare, LLC
Issues related to domestic generic pharmaceutical manufacturingManufacturing, Health issues
Two or more unrelated kinds of records unusual within 30 days
19 May 2026confirmed
Confirmed across sources Institutional holdings and Short interest and volume
Amneal Pharmaceuticals(AMRX): had 11.5M shares sold short in the 30 Apr 2026 report, 1.9× the same report last year, while it saw 69 13F filers open a new position in the quarter ended 31 Mar 2026, 1.5× the same quarter last year. Two unrelated kinds of activity within 7 days.
Short interest and volume: Short interest spike, became public on 12 May 2026
Institutional holdings: Many funds opening a new position, became public on 15 May 2026
The 30 Apr 2026 report against the 24 reports before it.
this reportearliernormal: 5.9MSee the evidence (2 changes)
Short interest and volume: Short interest spike became public on 12 May 2026
Amneal Pharmaceuticals had 11.5M shares sold short in the 30 Apr 2026 report, 1.9× the same report last year.
This period
11.5M (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
5.9M
Typical spread (median absolute deviation)
832K
How far from its usual level
+4.5
Same report last year
6.1M
History used
2,907 days
the 30 Apr 2026 report24 earlier reportsnormal: 5.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2026
Amneal Pharmaceuticals saw 69 13F filers open a new position in the quarter ended 31 Mar 2026, 1.5× the same quarter last year.
This period
69 (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
31.5
Typical spread (median absolute deviation)
4
How far from its usual level
+6.3
Same quarter last year
46
History used
2,831 days
the quarter ended 31 Mar 20268 earlier quartersnormal: 31.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 May 2025confirmed
Confirmed across sources Institutional holdings and Lobbying
Amneal Pharmaceuticals(AMRX): lobbying on a new issue, while it saw 46 13F filers open a new position in the quarter ended 31 Mar 2025, 1.7× the same quarter last year. Two unrelated kinds of activity within 24 days.
Lobbying: Lobbying on a new issue, became public on 21 Apr 2025
Institutional holdings: Many funds opening a new position, became public on 15 May 2025
The quarter ended 31 Mar 2025 against the 8 quarters before it.
this quarterearliernormal: 27See the evidence (2 changes)
Lobbying: Lobbying on a new issue became public on 21 Apr 2025
Amneal Pharmaceuticals lobbying on a new issue.
New
['MAN']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6138169
Institutional holdings: Many funds opening a new position became public on 15 May 2025
Amneal Pharmaceuticals saw 46 13F filers open a new position in the quarter ended 31 Mar 2025, 1.7× the same quarter last year.
This period
46 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
27
Typical spread (median absolute deviation)
3
How far from its usual level
+4.3
Same quarter last year
27
History used
2,466 days
the quarter ended 31 Mar 20258 earlier quartersnormal: 27
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
had 11.5M shares sold short in the 30 Apr 2026 report, 1.9× the same report last year, while it saw 69 13F filers open a new position in the quarter ended 31 Mar 2026, 1.5× the same quarter last year. Two unrelated kinds of activity within 7 days.
See the evidence (2 changes)
Short interest and volume: Short interest spike became public on 12 May 2026
Amneal Pharmaceuticals had 11.5M shares sold short in the 30 Apr 2026 report, 1.9× the same report last year.
This period
11.5M (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
5.9M
Typical spread (median absolute deviation)
832K
How far from its usual level
+4.5
Same report last year
6.1M
History used
2,907 days
the 30 Apr 2026 report24 earlier reportsnormal: 5.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2026
Amneal Pharmaceuticals saw 69 13F filers open a new position in the quarter ended 31 Mar 2026, 1.5× the same quarter last year.
This period
69 (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
31.5
Typical spread (median absolute deviation)
4
How far from its usual level
+6.3
Same quarter last year
46
History used
2,831 days
the quarter ended 31 Mar 20268 earlier quartersnormal: 31.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 May 2026Institutional holdings change
saw 69 13F filers open a new position in the quarter ended 31 Mar 2026, 1.5× the same quarter last year.
Same quarter last year: 46; its normal quarter is 31.5.
See the evidence
This period
69 (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
31.5
Typical spread (median absolute deviation)
4
How far from its usual level
+6.3
Same quarter last year
46
History used
2,831 days
the quarter ended 31 Mar 20268 earlier quartersnormal: 31.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 11.5M shares sold short in the 30 Apr 2026 report, 1.9× the same report last year.
Same report last year: 6.1M; its normal report is 5.9M.
See the evidence
This period
11.5M (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
5.9M
Typical spread (median absolute deviation)
832K
How far from its usual level
+4.5
Same report last year
6.1M
History used
2,907 days
the 30 Apr 2026 report24 earlier reportsnormal: 5.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.8M shares sold short in the 13 Mar 2026 report, 3.4× the same report last year.
Same report last year: 3.2M; its normal report is 5.5M.
See the evidence
This period
10.8M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
5.5M
Typical spread (median absolute deviation)
616K
How far from its usual level
+5.9
Same report last year
3.2M
History used
2,859 days
the 13 Mar 2026 report24 earlier reportsnormal: 5.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.9M shares sold short in the 27 Feb 2026 report, 3.6× the same report last year.
Same report last year: 2.8M; its normal report is 5.4M.
See the evidence
This period
9.9M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
5.4M
Typical spread (median absolute deviation)
660K
How far from its usual level
+4.6
Same report last year
2.8M
History used
2,845 days
the 27 Feb 2026 report24 earlier reportsnormal: 5.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.6M shares sold short in the 13 Feb 2026 report, 4.0× the same report last year.
Same report last year: 2.6M; its normal report is 5.4M.
See the evidence
This period
10.6M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
5.4M
Typical spread (median absolute deviation)
660K
How far from its usual level
+5.4
Same report last year
2.6M
History used
2,831 days
the 13 Feb 2026 report24 earlier reportsnormal: 5.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 12.7M shares sold short in the 30 Jan 2026 report, 5.2× the same report last year.
Same report last year: 2.4M; its normal report is 5.3M.
See the evidence
This period
12.7M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
5.3M
Typical spread (median absolute deviation)
660K
How far from its usual level
+7.5
Same report last year
2.4M
History used
2,817 days
the 30 Jan 2026 report24 earlier reportsnormal: 5.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $22.8M on capital projects in the quarter ended 30 Jun 2025, 2.1× the same quarter last year.
Same quarter last year: $10.6M; its normal quarter is $11.8M.
See the evidence
This period
$22.8M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$11.8M
Typical spread (median absolute deviation)
$1.6M
How far from its usual level
+4.5
Same quarter last year
$10.6M
History used
2,830 days
the quarter ended 30 Jun 20258 earlier quartersnormal: $11.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
lobbying on a new issue, while it saw 46 13F filers open a new position in the quarter ended 31 Mar 2025, 1.7× the same quarter last year. Two unrelated kinds of activity within 24 days.
See the evidence (2 changes)
Lobbying: Lobbying on a new issue became public on 21 Apr 2025
Amneal Pharmaceuticals lobbying on a new issue.
New
['MAN']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6138169
Institutional holdings: Many funds opening a new position became public on 15 May 2025
Amneal Pharmaceuticals saw 46 13F filers open a new position in the quarter ended 31 Mar 2025, 1.7× the same quarter last year.
This period
46 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
27
Typical spread (median absolute deviation)
3
How far from its usual level
+4.3
Same quarter last year
27
History used
2,466 days
the quarter ended 31 Mar 20258 earlier quartersnormal: 27
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 May 2025Institutional holdings change
saw 46 13F filers open a new position in the quarter ended 31 Mar 2025, 1.7× the same quarter last year.
Same quarter last year: 27; its normal quarter is 27.
See the evidence
This period
46 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
27
Typical spread (median absolute deviation)
3
How far from its usual level
+4.3
Same quarter last year
27
History used
2,466 days
the quarter ended 31 Mar 20258 earlier quartersnormal: 27
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 7.4M shares sold short in the 15 Mar 2023 report, 2.3× the same report last year.
Same report last year: 3.2M; its normal report is 4.1M.
See the evidence
This period
7.4M (the 15 Mar 2023 report)
Normal report (median of 24 earlier)
4.1M
Typical spread (median absolute deviation)
614K
How far from its usual level
+3.7
Same report last year
3.2M
History used
1,765 days
the 15 Mar 2023 report24 earlier reportsnormal: 4.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.1M shares sold short in the 28 Feb 2023 report, 2.4× the same report last year.
Same report last year: 2.9M; its normal report is 3.9M.
See the evidence
This period
7.1M (the 28 Feb 2023 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
598K
How far from its usual level
+3.6
Same report last year
2.9M
History used
1,750 days
the 28 Feb 2023 report24 earlier reportsnormal: 3.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.1M shares sold short in the 15 Feb 2023 report, 2.8× the same report last year.
Same report last year: 2.9M; its normal report is 3.8M.
See the evidence
This period
8.1M (the 15 Feb 2023 report)
Normal report (median of 24 earlier)
3.8M
Typical spread (median absolute deviation)
542K
How far from its usual level
+5.2
Same report last year
2.9M
History used
1,737 days
the 15 Feb 2023 report24 earlier reportsnormal: 3.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.1M shares sold short in the 31 Jan 2023 report, 4.1× the same report last year.
Same report last year: 2.2M; its normal report is 3.8M.
See the evidence
This period
9.1M (the 31 Jan 2023 report)
Normal report (median of 24 earlier)
3.8M
Typical spread (median absolute deviation)
542K
How far from its usual level
+6.6
Same report last year
2.2M
History used
1,722 days
the 31 Jan 2023 report24 earlier reportsnormal: 3.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.2M shares sold short in the 13 Jan 2023 report, 3.9× the same report last year.
Same report last year: 2.1M; its normal report is 3.7M.
See the evidence
This period
8.2M (the 13 Jan 2023 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
532K
How far from its usual level
+5.7
Same report last year
2.1M
History used
1,704 days
the 13 Jan 2023 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.7M shares sold short in the 30 Dec 2022 report, 2.7× the same report last year.
Same report last year: 2.8M; its normal report is 3.7M.
See the evidence
This period
7.7M (the 30 Dec 2022 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
494K
How far from its usual level
+5.5
Same report last year
2.8M
History used
1,690 days
the 30 Dec 2022 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $29.5M on capital projects in the quarter ended 31 Dec 2020, 6.5× the same quarter last year.
Same quarter last year: $4.5M; its normal quarter is $11.3M.
See the evidence
This period
$29.5M (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
$11.3M
Typical spread (median absolute deviation)
$3.4M
How far from its usual level
+3.7
Same quarter last year
$4.5M
History used
1,188 days
the quarter ended 31 Dec 20208 earlier quartersnormal: $11.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
"First" means first in our data: it fires only when the source's history began at least 365 days earlier.
Showing the newest 40 of 93 entries; narrow the window or the kind of data to see older ones.
Not listed: 148 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001723128
Ticker
AMRX
Domain
amneal.com
Employer name
AMNEAL PHARMACEUTICALS LLC, AMNEAL PHARMACEUTICALS OF NEW YORK, Impax Laboratories (3 unverified)
Lobbying client
amneal pharmaceuticals, atlas frm llc d b a atlas holdings, brown rudnick llp on behalf of amneal pharmaceuticals
Name
Amedra Pharmaceuticals LLC, Amneal Biopharma Solutions Private Limited, Amneal Biopharma Synthesis Private Limited, Amneal Biosciences LLC and 29 more
Uei
HCARMCN67GH6, LVEBAQTPN615, NBK9JTF9JHL4, THNFXMFLGE75 and 1 more
Wikidata
Q16996714
Wikipedia
Amneal Pharmaceuticals
DOL H-1B labor condition applications and PERM certifications772 data points1 Oct 2019 to 7 Sep 2026
Federal lobbying disclosures (LDA)11 records, 123 data points8 Nov 2013 to 30 Sep 2026
SEC Form 13F institutional holdings306 data points30 Jun 2018 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)130 records7 Mar 2018 to 9 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)626 data points31 Dec 2015 to 30 Oct 2026
SEC Form 4 insider transactions68 records, 200 data points8 May 2018 to 14 Aug 2026
FINRA short interest (twice monthly)608 data points15 May 2018 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards1 record, 765 data points31 Jul 2018 to 8 Mar 2024
WARN layoff notices (state labor agencies)1 record, 3 data points30 Jan 2017 to 1 Feb 2017
Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026